诺氟沙星和环丙沙星对结核分枝杆菌、鸟分枝杆菌复合体、龟分枝杆菌、偶然分枝杆菌和堪萨斯分枝杆菌的体外活性。
In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
作者信息
Gay J D, DeYoung D R, Roberts G D
出版信息
Antimicrob Agents Chemother. 1984 Jul;26(1):94-6. doi: 10.1128/AAC.26.1.94.
Abstract
The activities of ciprofloxacin and norfloxacin against 100 mycobacteria isolates were studied in vitro by the 1% standard proportion method. Ciprofloxacin was more active against M. tuberculosis and M. fortuitum with MICs of 1.0 and 0.25 microgram/ml, respectively, against 90% of isolates; norfloxacin had MICs of 8.0 and 2.0 micrograms/ml, respectively, against 90% of isolates.
摘要
采用1%标准比例法，在体外研究了环丙沙星和诺氟沙星对100株分枝杆菌分离株的活性。环丙沙星对结核分枝杆菌和偶然分枝杆菌活性更强，对90%的分离株，其最低抑菌浓度（MIC）分别为1.0和0.25微克/毫升；诺氟沙星对90%的分离株，其MIC分别为8.0和2.0微克/毫升。
相似文献
1
In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.诺氟沙星和环丙沙星对结核分枝杆菌、鸟分枝杆菌复合体、龟分枝杆菌、偶然分枝杆菌和堪萨斯分枝杆菌的体外活性。
Antimicrob Agents Chemother. 1984 Jul;26(1):94-6. doi: 10.1128/AAC.26.1.94.
2
Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.环丙沙星及其他4-喹诺酮类药物对结核分枝杆菌和胞内分枝杆菌的体外活性比较
Antimicrob Agents Chemother. 1986 Mar;29(3):386-8. doi: 10.1128/AAC.29.3.386.
3
Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.环丙沙星及其他氟喹诺酮类药物对分枝杆菌的活性。
Am J Med. 1987 Apr 27;82(4A):23-6.
4
Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.环丙沙星（拜奥9867）、诺氟沙星、吡哌酸和萘啶酸的比较活性。
Antimicrob Agents Chemother. 1983 Aug;24(2):302-4. doi: 10.1128/AAC.24.2.302.
5
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.环丙沙星、诺氟沙星、恶喹酸、西诺沙星和萘啶酸的抗菌活性。
Antimicrob Agents Chemother. 1984 May;25(5):633-7. doi: 10.1128/AAC.25.5.633.
6
Comparative in-vitro activity of five fluoroquinolones against mycobacteria.五种氟喹诺酮类药物对分枝杆菌的体外活性比较
J Antimicrob Chemother. 1987 May;19(5):605-9. doi: 10.1093/jac/19.5.605.
7
In-vitro susceptibility of mycobacteria to ciprofloxacin.分枝杆菌对环丙沙星的体外敏感性
J Antimicrob Chemother. 1985 Nov;16(5):575-80. doi: 10.1093/jac/16.5.575.
8
In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.四种氟喹诺酮类药物对86株分枝杆菌的体外活性
Eur J Clin Microbiol. 1987 Oct;6(5):584-6. doi: 10.1007/BF02014255.
9
In vitro activity of ciprofloxacin (Bay o 9867).环丙沙星（拜耳o 9867）的体外活性。
Antimicrob Agents Chemother. 1983 Oct;24(4):568-74. doi: 10.1128/AAC.24.4.568.
10
The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.环丙沙星与诺氟沙星和萘啶酸的体外活性比较。
J Antimicrob Chemother. 1984 Apr;13(4):325-31. doi: 10.1093/jac/13.4.325.
引用本文的文献
1
pH-driven enhancement of anti-tubercular drug loading on iron oxide nanoparticles for drug delivery in macrophages.pH驱动增强巨噬细胞药物递送中氧化铁纳米颗粒上抗结核药物的负载量
Beilstein J Nanotechnol. 2021 Oct 7;12:1127-1139. doi: 10.3762/bjnano.12.84. eCollection 2021.
2
An ADME and Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives.新型抗结核药地考喹酯衍生物的吸收、分布、代谢和排泄及药代动力学研究
Front Pharmacol. 2019 Feb 18;10:120. doi: 10.3389/fphar.2019.00120. eCollection 2019.
3
Analysis of DNA gyrA Gene Mutation in Clinical and Environmental Ciprofloxacin-Resistant Isolates of Non-Tuberculous Mycobacteria Using Molecular Methods.运用分子方法分析临床和环境中耐环丙沙星的非结核分枝杆菌分离株的DNA促旋酶A基因突变情况。
Jundishapur J Microbiol. 2016 Mar 11;9(3):e30018. doi: 10.5812/jjm.30018. eCollection 2016 Mar.
4
Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients.耐多药结核病患者中氟喹诺酮类药物的耐药模式、流行情况及耐药预测因素
Braz J Infect Dis. 2016 Jan-Feb;20(1):41-7. doi: 10.1016/j.bjid.2015.09.011. Epub 2015 Nov 25.
5
Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.脂质体包裹环丙沙星在鼠型Q热模型中的疗效
Antimicrob Agents Chemother. 2014 Sep;58(9):5510-8. doi: 10.1128/AAC.03443-14. Epub 2014 Jul 7.
6
Mycobacterium paraffinicum causing symptomatic pulmonary infection.引起症状性肺部感染的石蜡分枝杆菌。
J Clin Microbiol. 2014 Apr;52(4):1281-3. doi: 10.1128/JCM.03107-13. Epub 2014 Jan 22.
7
Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.氟喹诺酮类药物的环境代谢物：环丙沙星的一些生物活性代谢物的合成、分离和毒理学评价。
Environ Sci Pollut Res Int. 2011 Aug;19(7):2697-707. doi: 10.1007/s11356-012-0766-7. Epub 2012 Feb 4.
8
New drugs and regimens for treatment of TB.新型抗结核药物及治疗方案。
Expert Rev Anti Infect Ther. 2010 Jul;8(7):801-13. doi: 10.1586/eri.10.60.
9
Triggered release of ciprofloxacin from nanostructured agglomerated vesicles.环丙沙星从纳米结构团聚囊泡中的触发释放。
Int J Nanomedicine. 2007;2(3):407-18.
10
First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.针对HIV阴性患者中由胞内鸟分枝杆菌、马尔默分枝杆菌和蟾分枝杆菌引起的肺部疾病治疗的首个随机试验：利福平、乙胺丁醇和异烟肼与利福平和乙胺丁醇的对比
Thorax. 2001 Mar;56(3):167-72. doi: 10.1136/thorax.56.3.167.
本文引用的文献
1
Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.磺胺对偶然分枝杆菌和龟分枝杆菌的活性。
Rev Infect Dis. 1981 Sep-Oct;3(5):898-904. doi: 10.1093/clinids/3.5.898.
2
In vitro susceptibility of Mycobacterium fortuitum to cefoxitin.偶然分枝杆菌对头孢西丁的体外敏感性
Antimicrob Agents Chemother. 1981 Jan;19(1):205-7. doi: 10.1128/AAC.19.1.205.
3
Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.快速生长分枝杆菌：采用肉汤微量稀释法检测对34种抗菌药物的敏感性
Antimicrob Agents Chemother. 1982 Aug;22(2):186-92. doi: 10.1128/AAC.22.2.186.
4
Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.新型有机酸诺氟沙星（MK 0366，AM 715）与其他口服吸收的化疗药物抗菌活性的比较。
Infection. 1982 Jan;10(1):41-4. doi: 10.1007/BF01640837.
5
Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.Mk-0366与其他选定口服抗菌剂对淋病奈瑟菌的体外活性比较
Antimicrob Agents Chemother. 1981 Aug;20(2):265-6. doi: 10.1128/AAC.20.2.265.
6
Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.诺氟沙星在健康志愿者以及肾、肝损伤患者中的药代动力学。
Eur J Clin Microbiol. 1983 Jun;2(3):253-9. doi: 10.1007/BF02029528.
7
Comparative in vitro activity of norfloxacin against urinary tract pathogens.诺氟沙星对泌尿道病原体的体外活性比较
Eur J Clin Microbiol. 1983 Jun;2(3):235-41. doi: 10.1007/BF02029524.
8
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.环丙沙星、诺氟沙星和萘啶酸的体外活性。
Eur J Clin Microbiol. 1983 Apr;2(2):111-5. doi: 10.1007/BF02001575.
9
Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.诺氟沙星与抗菌性γ-吡啶酮β-羧酸类化合物。
J Antimicrob Chemother. 1982 Jul;10(1):25-30. doi: 10.1093/jac/10.1.25.
10
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.诺氟沙星（MK-0366）与其他十种口服抗菌药物对尿细菌分离株的体外活性比较
Antimicrob Agents Chemother. 1982 May;21(5):848-51. doi: 10.1128/AAC.21.5.848.
Zotero 插件